Rabbit nasal immunization against influenza by dry-powder form of chitosan nanospheres encapsulated with influenza whole virus and adjuvants

Dehghan, Solmaz; Tafaghodi, Mohsen; Bolourieh, Tina; Mazaheri, Vahideh; Abnous, Khalil; Kheiri, Masoumeh Tavassoti

doi:10.1016/j.ijpharm.2014.08.032

Cited by 38 publications

(22 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When challenged with E. tarda after immunization, fish in the group of rGAPDH containing β-glucan showed the particles also enhanced the release of proinflammation cytokines, IL-1β, IL-6, TNF-α, MCP-1 and MIP-1α, as well as the proliferation of CD4 + and CD8 + T cells (19). Dry-powder chitosan nanospheres encapsulated with influenza virus, CpG oligodexynucleotide (CpG ODN) and Quillaja saponins (QS) induced humoral and cellular immune responses after nasal administration to rabbits (20). It is thought that dry powder particulate system provides long lasting protective immunity, and offers physical and chemical stability for antigens (21,22).…”

Section: Glucan-based Adjuvantmentioning

confidence: 99%

“…It is thought that dry powder particulate system provides long lasting protective immunity, and offers physical and chemical stability for antigens (21,22). Chitosan nanospheres delivery system elevated both local sIgA and systemic IgG titers against the virus, suggesting this nanoparticulate chitosan may be an efficient adjuvant delivery system for immunization against influenza virus (20). Similar to chitosan, its trimethylated derivative (TMC) nanoparticles loaded with HBsAg given to mice intranasally and intramuscularly induced higher nasal and serum antibody titers than HBsAg solution.…”

Section: Glucan-based Adjuvantmentioning

confidence: 99%

See 1 more Smart Citation

Polysaccharides: Candidates of promising vaccine adjuvants

Wang

2015

DD&T

107

View full text Add to dashboard Cite

Aluminium-based adjuvants remain the only adjuvants approved for human use in the USA for over 80 years because of alum's simplicity, tolerability, safety and cost-efficiency. Recent development of vaccines, especially the increasing applications of recombinant subunit and synthetic vaccines, makes aluminium adjuvants cannot stimulate enough immunity to the antigens, since aluminium adjuvants can only induce Th2 type immune responses. So, novel adjuvants are urgent to make up the disadvantages of aluminium adjuvants. However, some major hurdles need to be overcome, not only the scientific knowledge of adjuvants but also unacceptable side-effects and toxicity. A number of carbohydrate-based polysaccharides from plant, bacterial, yeast and synthetic sources can act as pathogen-associated molecular patterns (PAMPs) and recognize pattern recognition receptors (PRRs) on immune cells, followed by triggering innate immunity and regulating adaptive immunity. What is more, polysaccharides are safe and biodegradable without tissue deposits as observed in aluminium adjuvants. Therefore, polysaccharide-based compounds and formulations are potential vaccine adjuvant candidates. Here, we mainly review polysaccharide-based adjuvants investigated in recent years.

show abstract

Section: Glucan-based Adjuvantmentioning

confidence: 99%

Section: Glucan-based Adjuvantmentioning

confidence: 99%

Polysaccharides: Candidates of promising vaccine adjuvants

Wang

2015

DD&T

107

View full text Add to dashboard Cite

show abstract

“… 2001 ; Dehghan et al. 2014 ). In spite of the negative impact of CDM on the systemic IgG titres, they didn’t show any significant effect on mucosal sIgA titres.…”

Section: Discussionmentioning

confidence: 99%

Immunoadjuvant potential of cross-linked dextran microspheres mixed with chitosan nanospheres encapsulated with tetanus toxoid

Pirouzmand

Khameneh

Tafaghodi

2016

Pharmaceutical Biology

Self Cite

View full text Add to dashboard Cite

Context: Nasal mucosa is a desirable route for mucosal vaccine delivery. Mucosal co-administration of chitosan nanoparticles with absorption enhancers such as cross-linked dextran microspheres (CDM, Sephadex®) is a promising antigen delivery system.Objective: In the current study, the chitosan nanospheres loaded with tetanus toxoid (CHT:TT NPs) was prepared and characterized. The immune responses against tetanus toxoid after nasal administration of CHT:TT NPs alone or mixed with CDM were also determined.Materials and methods: Chitosan nanospheres were prepared by ionic gelation method. Particle size, releasing profile and antigen stability were evaluated by dynamic light scattering, diffusion chamber and SDS-PAGE methods, respectively. Rabbits were nasally immunized with different formulations loaded with 40 Lf TT. After three times immunizations with 2 weeks intervals, sera IgG titres and nasal lavage sIgA titres were determined.Results: Mean size of CHT NPs and CHT:TT NPs were 205 ± 42 nm and 432 ± 85 nm, respectively. The release profile showed that 42.4 ± 10.5% of TT was released after 30 min and reached to a steady state after 1.5 h. Stability of encapsulated TT in nanospheres was confirmed by SDS-PAGE. The antibody titres showed that CHT:TT NPs-induced antibody titres were higher than TT solution. CHT NPs mixed with CDM induced the systemic IgG and nasal lavage sIgA titres higher than intranasal administration of TT solution (p < 0.001).Discussion and conclusion: As the results indicated, these CHT:TT NPs when co-administered with CDM were able to induce more immune responses and have the potential to be used in mucosal immunization.

show abstract

“…Nanovaccines have been developed to induce mucosal protection from influenza virus. Successful nasal immunization was achieved in rabbits immunized with whole influenza virus incorporated into a mucoadhesive carrier chitosan; significant levels of anti-hemagglutinin antibody, local anti-influenza virus IgA, systemic IL-2, and IFN-γ were detected in the serum [ 131 ]. Another successful nanovaccine was established by adsorbing both inactivated swine influenza virus antigens and TLR3 agonist poly(I:C) onto cationic alpha- d -glucan NPs [ 132 ].…”

Section: Nano-based Vaccinesmentioning

confidence: 99%